The trial will analyse XMT-1660 for treating individuals with solid tumours, including endometrial and ovarian cancers. Credit: KGH / commons.wikimedia.org.

Mersana Therapeutics has commenced the dosing of subjects in the Phase I clinical trial of XMT-1660 to treat individuals with solid tumours, including breast, endometrial, and ovarian cancers. 

The multicentre trial will assess XMT-1660’s safety, tolerability, and anti-tumour activity in such solid tumour patients. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The preliminary dose escalation part of the trial will analyse the safety and tolerability of XMT-1660 as a monotherapy. 

In the dose expansion segment of the trial, the tolerability and efficacy of XMT-1660 will be evaluated. 

Investigator-evaluated objective response rate and duration of response are the primary endpoints of this portion of the trial.

See Also:

XMT-1660 is a Dolasynthen antibody-drug conjugate (ADC) that acts on B7-H4.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has a target-streamlined drug-to-antibody ratio and the company’s DolaLock microtubule inhibitor payload established clinically, with a controlled bystander effect. 

B7-H4 is overexpressed in various cancers, including breast, endometrial, and ovarian tumours. 

The therapy also showed strong anti-tumour activity in various models representing each of these cancer types and in multiple patient-obtained xenograft models in pre-clinical studies.

Mersana Therapeutics president and CEO Anna Protopapas said: “The initiation of this Phase I trial represents an important milestone for Mersana as we continue to build our pipeline across three ADC platforms and seek to further demonstrate the potential of our Dolalock payload and Dolasynthen platform. 

“Based on our promising preclinical data, we believe XMT-1660 has the potential to serve as a highly impactful cancer treatment.”

The clinical-stage biopharma firm discovers and develops ADCs that act on cancers in areas of increased unmet medical need.